29
2024-10
KT-939 INCI Name & Expand To Whitening And Freckle-Removing
Suzhou, 29 Oct 2024-Kintor Pharma announced that KT-939 received INCI name and expand to whitening and freckle-removing.
05
2024-08
BEIJING, Aug. 5, 2024 - Pioneering Pharmaceuticals (HKEx: 9939.HK), a biopharmaceutical company focusing on the research, development and industrialization of potentially first-of-its-kind and best-of-breed innovative medicines, announced that the investigators' meeting of the Registered Phase II/III Clinical Trial of KX-826 Tincture for the Topical Treatment of Androgenetic Alopecia in Chinese Adult Males (AGA), which is being conducted by Prof. Zhang Jianzhong and Prof. Zhou Cheng of Peking University People's Hospital as Leading PIs, was successfully held in Beijing, China, on Aug. 4th.
10
2024-07
Cosmetics with KX-826 as the core ingredient launched for sale
Beijing, July 10, 2024, Pioneering Pharmaceuticals (stock code: 9939.HK), announced that after its self-developed KX-826 was awarded the International Named Cosmetic Ingredient (INCI) designation, the cosmetic products with KX-826 as the main ingredient have been officially launched for sale globally in the recent days, and the first product is the topical anti-baldness solution targeting at androgenic alopecia (AGA).
01
2024-07
KX-826 Androgen receptor antagonist
KX-826 is a topical androgen receptor (AR) antagonist, the world's first AR antagonist for the treatment of alopecia areata to enter registrational Phase III clinical trials.
17
2024-06
Suzhou, June 17, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has completed the first subject enrollment in the phase II clinical trial in China of its in-house developed androgen receptor proteolysis targeting chimera (“PROTAC”) compound GT20029 for the treatment of acne.
05
2024-06
KX-826 Received The INCI Designation
June 5, 2024-Kintor Pharmaceutical Limited announced that KX-826 received the INCI designation.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn